Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Proton Beam Therapy Useful in Treating Sinonasal Cancers

By HospiMedica International staff writers
Posted on 11 Mar 2010
Proton beam-radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a new study.

Researchers at Massachusetts General Hospital (MGH; Boston, USA) treated 99 patients with newly diagnosed sinonasal cancers with proton beam therapy between 1991 and 2003, with the median total dose of radiation to the primary tumor at 70 Gray. More...
Most of the patients (67%), who usually presented with advanced stage tumors involving normal structures in the skull base such as eyes, optic nerves, brain, had undergone some type of surgery prior to their radiation. The researchers found that after a median follow-up of 8.5 years, the local control rates at five and eight years were 87% and 83%, respectively, and there was no statistically significant difference in local control per histological subtype, T stage, and surgery compared to biopsy. The study was presented at the Multidisciplinary Head and Neck Cancer Symposium, held during February 2010 in Chandler (AZ, USA).

"Due to the anatomical location of sinonasal cancers, conventional radiation therapy results in very poor local control and is associated with significant treatment-related toxicity,” said lead author radiation oncologist Annie Chan, M.D., of MGH and Harvard Medical School (Boston, MA, USA). "Proton beam radiation therapy, with its superior dose distribution, allows the delivery of higher doses of radiation to the tumor while sparing more or the healthy surrounding tissues. This study showed very encouraging results for these patients and now prospective multi-institutional studies are being planned to further study the use of proton therapy in the treatment of this rare but aggressive malignancy.”

Proton beam therapy is a form of particle therapy, which uses a stream of protons to irradiate diseased tissue, most often in the treatment of cancer. During treatment, a particle accelerator is used to target the tumor; these charged particles damage the DNA of cells, ultimately causing their death or interfering with their ability to reproduce. The chief advantage of proton therapy is increased precision by emphasizing the reduction of the integral dose to normal tissue, and thus a reduction of unwanted effects. The development of proton therapy began in the 1950s at accelerator laboratories, and in the last 20 years has expanded to hospital based facilities built specifically to perform this type of treatment. There are currently only 26 proton therapy centers worldwide, due to the size and cost of the cyclotron or synchrotron equipment needed.

Related Links:
Massachusetts General Hospital
Harvard Medical School


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Medical-Grade Display
HL2316SHTB
Wound Irrigation Solution
Prontosan®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image Credit: Adobe Stock

New ECG Foundation Model Enables Broad Cardiac Diagnosis and Risk Prediction

Electrocardiograms are central to cardiovascular decision-making, but conventional artificial intelligence models are often trained for narrow tasks, such as detecting a single arrhythmia.... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.